MCID: CNN010
MIFTS: 46

Connective Tissue Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

MalaCards integrated aliases for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 15
Soft Tissue Neoplasms 54 43 71
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12
Soft Tissue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 43 D012983
NCIt 49 C3377
UMLS 71 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to glomangiosarcoma and desmoid tumor. An important gene associated with Connective Tissue Benign Neoplasm is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are ERK Signaling and Human cytomegalovirus infection. The drugs Cyclophosphamide and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, bone and liver, and related phenotypes are behavior/neurological and cellular

Related Diseases for Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 380)
# Related Disease Score Top Affiliating Genes
1 glomangiosarcoma 32.6 CD34 CALD1
2 desmoid tumor 32.4 KIT HBEGF CTNNB1 CD34 AFAP1
3 bone benign neoplasm 31.9 USP6 SERPINA3 MRPL49 GNAS ERCC6 CDC73
4 spindle cell sarcoma 31.3 SERPINA3 MDM2 CD34
5 hemangiopericytoma, malignant 31.2 SERPINA3 MDM2 KIT CD34 CALD1
6 fibroma 31.2 USP6 TSC1 SERPINA3 PTCH1 GNAS CTNNB1
7 dermatofibrosarcoma protuberans 31.0 SERPINA3 KIT CDK4 CD34
8 hemangioma 30.7 TSC2 KIT CD68 CD34
9 pleomorphic lipoma 30.7 SERPINA3 MDM2 CDK4 CD34
10 infiltrating lipoma 30.7 MDM2 CDK4
11 neurofibroma 30.6 NF1 KIT CD34
12 well-differentiated liposarcoma 30.6 MDM2 CDK4 CD34
13 leiomyosarcoma 30.6 SERPINA3 NF1 MDM2 KIT CDK4
14 neurofibromatosis, type iv, of riccardi 30.6 TSC2 NF1 KIT
15 perivascular epithelioid cell tumor 30.5 TSC2 KIT CALD1
16 tuberous sclerosis 1 30.5 TSC2 TSC1 SERPINA3
17 glomus tumor 30.5 CD34 CALD1 CALB2
18 fibrous histiocytoma 30.5 SERPINA3 CD68 CD34
19 plexiform schwannoma 30.5 NF1 KIT CD34
20 neurofibrosarcoma 30.5 NF1 KIT CD34
21 angiomyolipoma 30.4 TSC2 TSC1 KIT
22 cutaneous fibrous histiocytoma 30.4 SERPINA3 CD68 CD34
23 plexiform neurofibroma 30.4 NF1 KIT CD34
24 chondrosarcoma, extraskeletal myxoid 30.4 KIT CD34 CALD1
25 granular cell tumor 30.4 SERPINA3 CD68 CALB2
26 smooth muscle tumor 30.4 SERPINA3 KIT CD34 CALD1
27 leiomyoma 30.4 TSC2 PTCH1 KIT CD34
28 epithelioid sarcoma 30.4 CD68 CD34 CALB2
29 adenoma 30.3 TSC1 GNAS CTNNB1 CDC73
30 histiocytoma 30.3 SERPINA3 MDM2 KIT CDK4 CD68 CD34
31 lipomatosis, multiple 30.2 SERPINA3 NF1 MDM2 KIT CDK4 CD34
32 malignant fibroxanthoma 30.2 SERPINA3 MDM2 CDK4 CD68 CD34
33 neuroma 30.2 SERPINA3 NF1 CD68 CD34
34 malignant peripheral nerve sheath tumor 30.2 NF1 MDM2 KIT CDK4 CD34
35 mesenchymal cell neoplasm 30.2 SERPINA3 NF1 KIT CD68 CD34 CALD1
36 neurilemmoma 30.1 SERPINA3 NF1 KIT CD34 CALB2
37 pseudosarcomatous fibromatosis 30.1 USP6 SERPINA3 CTNNB1 CD68 CD34 CALD1
38 ewing sarcoma 30.1 NF1 MDM2 KIT CDK4 CD34
39 angiosarcoma 30.1 MDM2 KIT CD68 CD34 CALB2
40 liposarcoma 29.9 MDM2 CTNNB1 CDK4 CD68 CD34 CALB2
41 inflammatory myofibroblastic tumor 29.9 MDM2 KIT CDK4 CD68 CD34 CALD1
42 sarcoma, synovial 29.8 SERPINA3 NF1 MDM2 KIT CTNNB1 CD34
43 sarcoma 11.8
44 infantile myofibromatosis 11.3
45 spleen angiosarcoma 11.2
46 angiolipoma 10.7 MDM2 CD34
47 ring chromosome 7 10.7 MDM2 CDK4
48 mediastinum liposarcoma 10.7 MDM2 CDK4
49 spinal cord sarcoma 10.7 KIT CD34
50 glomangioma 10.7 CD34 CALD1

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 AFAP1 CALB2 CDC73 CDK4 CTNNB1 ERCC6
2 cellular MP:0005384 10.38 CD34 CDC73 CDK4 CTNNB1 ERCC6 GNAS
3 integument MP:0010771 10.36 AFAP1 CD34 CDC73 CDK4 CTNNB1 ERCC6
4 cardiovascular system MP:0005385 10.35 CDC73 CDK4 CTNNB1 GNAS HBEGF KIT
5 growth/size/body region MP:0005378 10.35 CDC73 CDK4 CTNNB1 ERCC6 GNAS HBEGF
6 homeostasis/metabolism MP:0005376 10.35 CD34 CDC73 CDK4 CTNNB1 ERCC6 GNAS
7 hematopoietic system MP:0005397 10.33 CD34 CD68 CDC73 CDK4 CTNNB1 ERCC6
8 endocrine/exocrine gland MP:0005379 10.32 AFAP1 CDC73 CDK4 CTNNB1 GNAS KIT
9 immune system MP:0005387 10.26 CD34 CD68 CDC73 CDK4 CTNNB1 ERCC6
10 embryo MP:0005380 10.24 CDC73 CDK4 CTNNB1 KIT MDM2 NF1
11 nervous system MP:0003631 10.22 CALB2 CDC73 CDK4 CTNNB1 ERCC6 GNAS
12 neoplasm MP:0002006 10.21 CD34 CDC73 CDK4 CTNNB1 ERCC6 GNAS
13 muscle MP:0005369 10.2 CDC73 CDK4 CTNNB1 ERCC6 GNAS HBEGF
14 craniofacial MP:0005382 10.19 CDC73 CDK4 CTNNB1 GNAS KIT MDM2
15 liver/biliary system MP:0005370 10.18 CDC73 CDK4 CTNNB1 ERCC6 GNAS KIT
16 limbs/digits/tail MP:0005371 10.04 CTNNB1 ERCC6 GNAS KIT MDM2 NF1
17 hearing/vestibular/ear MP:0005377 10.03 CTNNB1 ERCC6 GNAS KIT NF1 PTCH1
18 normal MP:0002873 10.02 CALB2 CDK4 CTNNB1 GNAS HBEGF KIT
19 no phenotypic analysis MP:0003012 9.91 AFAP1 CD68 CTNNB1 GNAS KIT MDM2
20 renal/urinary system MP:0005367 9.85 CDC73 CDK4 CTNNB1 GNAS KIT MDM2
21 pigmentation MP:0001186 9.8 CDK4 CTNNB1 KIT MDM2 NF1 PTCH1
22 respiratory system MP:0005388 9.56 CDC73 CTNNB1 GNAS HBEGF KIT NF1
23 skeleton MP:0005390 9.4 CD68 CDC73 CDK4 CTNNB1 ERCC6 GNAS

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
9
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
10 Antirheumatic Agents Phase 3
11 Antibodies, Monoclonal Phase 3
12 Immunoglobulins Phase 3
13 Antibodies Phase 3
14 Alkylating Agents Phase 3
15 Etoposide phosphate Phase 3
16 Topoisomerase Inhibitors Phase 3
17 Podophyllotoxin Phase 3 518-28-5
18 Immunosuppressive Agents Phase 3
19 Immunologic Factors Phase 3
20 Antibiotics, Antitubercular Phase 3
21 Anti-Bacterial Agents Phase 3
22
Liposomal doxorubicin Phase 3 31703
23
Isophosphamide mustard Phase 3 0
24 Antimitotic Agents Phase 3
25 topoisomerase I inhibitors Phase 3
26
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
27
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
28
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
29
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
30 Epinephryl borate Phase 1, Phase 2
31
s 1 (combination) Phase 1, Phase 2
32 Carboxymethylcellulose Sodium Phase 1, Phase 2
33
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
35
Lenograstim Approved, Investigational Phase 1 135968-09-1
36
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
37
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
38
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
39
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
40
Bevacizumab Approved, Investigational Phase 1 216974-75-3
41
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
42
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
43
Iodine Approved, Investigational Phase 1 7553-56-2 807
44 Anti-Inflammatory Agents Phase 1
45 Antiemetics Phase 1
46
protease inhibitors Phase 1
47 Autonomic Agents Phase 1
48 BB 1101 Phase 1
49 Gastrointestinal Agents Phase 1
50 Hormone Antagonists Phase 1

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
2 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
3 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
4 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
5 The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors Completed NCT00001189 Phase 2
6 SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES Completed NCT02066675 Phase 2 Trabectedin
7 Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors Recruiting NCT02285439 Phase 1, Phase 2 MEK162
8 A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma Completed NCT00102609 Phase 1 Doxorubicin;Trabectedin;Dexamethasone
9 Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Recruiting NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
10 Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on. Recruiting NCT03159585 Phase 1 TAEST16001
11 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
12 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
13 A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Terminated NCT02602067 Phase 1
14 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
15 Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002 Unknown status NCT00173355
16 Navigation Surgery for Bone and Soft Tissue Tumor Unknown status NCT01179698
17 Feasibility of the Third Space Robotic and Endoscopic Cooperative Surgery(TS-RECS) for Treating Gastric Stromal Tumor Completed NCT03804762
18 Radiofrequency Ablation of Painful Soft Tissue Neoplasms Completed NCT00041886
19 Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI Completed NCT01276483
20 Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors Completed NCT01630239 Early Phase 1
21 Quantitative MR Biomarkers for Sarcoma Treatment Completed NCT01017978
22 In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study Completed NCT01731379
23 Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors Recruiting NCT03452644
24 An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Recruiting NCT02677961
25 Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma Recruiting NCT02561559
26 Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study Recruiting NCT02557243
27 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT03737734
28 Osteoarticular Tumor Characterization by Advanced Imaging Recruiting NCT02895633
29 A Pilot Study of Photoacoustic Imaging (PAI) Recruiting NCT03630601
30 The Use of Liposomal Bupivacaine (Exparel) in Soft Tissue Sarcoma Resection Recruiting NCT03867188 Early Phase 1 Liposomal Bupivacaine
31 Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors Recruiting NCT03751566 Standard supportive therapy
32 Follow-up of Recurrences of Limb Soft Tissue Sarcomas in Patients With Localized Disease: Performance of Ultrasound Recruiting NCT02834585
33 Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites. Active, not recruiting NCT00582647
34 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Not yet recruiting NCT03889899
35 A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia Not yet recruiting NCT03886181
36 A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities Terminated NCT01965002 Aspirin;Enoxaparin
37 Prospective Multi-center National Swiss Sarcoma Cohort Study Terminated NCT02775799

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


docetaxel

Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

19
Connective Tissue

MalaCards organs/tissues related to Connective Tissue Benign Neoplasm:

40
Bone, Liver, Skin, Lung, Breast, Heart, Thyroid

Publications for Connective Tissue Benign Neoplasm

Articles related to Connective Tissue Benign Neoplasm:

(show top 50) (show all 482)
# Title Authors PMID Year
1
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 54 61
16707369 2006
2
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 54 61
16160477 2005
3
Soft tissue tumor diagnosis: A three prong approach utilizing pattern analysis, immunocytochemistry, and molecular diagnostics. 61
31868988 2020
4
Bone Sarcomas and Desmoids. 61
31739943 2020
5
What is new in epithelioid soft tissue tumors? 61
31686193 2020
6
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. 61
31913156 2020
7
Desmoplastic stromal changes in cutaneous neural granular cell tumors: An under-recognized histopathologic feature of diagnostic and prognostic importance. 61
31859431 2019
8
Genomic and transcriptomic features of dermatofibrosarcoma protuberans: Unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development. 61
31870844 2019
9
Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma? 61
31889532 2019
10
GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. 61
31189998 2019
11
Skin and superficial soft tissue neoplasms with multinucleated giant cells: Clinical, histologic, phenotypic, and molecular differentiating features. 61
31306855 2019
12
Is MRI diffusion-weighted imaging a reliable tool for the diagnosis and post-therapeutic follow-up of extremity soft tissue neoplasms? 61
31949339 2019
13
Asymptomatic esophageal glomus tumor: case report. 61
31602340 2019
14
PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. 61
31008539 2019
15
Isolated Breast Relapse after Metastatic Alveolar Rhabdomyosarcoma in a Young Premenarcheal Girl: What Could Have Been Done? 61
31911774 2019
16
Diffusion-weighted imaging and diffusion tensor imaging as adjuncts to conventional MRI for the diagnosis and management of peripheral nerve sheath tumors: current perspectives and future directions. 61
30535638 2019
17
Prevalence of Neoplasms among Former Adolescent Psychiatric Inpatients. 61
31389225 2019
18
[Myxoid soft tissue tumours : An algorithm for differential diagnosis]. 61
31168638 2019
19
Spindle Cell Sarcoma of the Paraspinal Musculature with Late Pulmonary Metastases. 61
31186400 2019
20
[Clinicopathological characteristics and differential diagnosis of interdigitating dendritic cell sarcoma]. 61
31216832 2019
21
MRI imaging of soft tissue tumours of the foot and ankle. 61
31161474 2019
22
Mesenchymal Tumors with EWSR1 Gene Rearrangements. 61
30709442 2019
23
Practical Application of Cytology and Core Biopsy in the Diagnosis of Mesenchymal Tumors. 61
30709446 2019
24
SWI/SNF Complex-Deficient Soft Tissue Neoplasms: A Pattern-Based Approach to Diagnosis and Differential Diagnosis. 61
30709441 2019
25
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. 61
30853708 2019
26
Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. 61
30350361 2019
27
Multinucleate cell angiohistiocytoma of the lower vermilion lip: an unusual site. 61
27706113 2019
28
Granular Cell Tumor over the Mons Pubis: An Uncommon Tumor. 61
31223510 2019
29
Biphasic Epithelial Predominant Synovial Sarcoma Presenting as Painful Thigh Mass. 61
31583005 2019
30
Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report. 61
30187166 2019
31
Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics. 61
30600320 2019
32
Imaging features of phosphaturic mesenchymal tumors. 61
29987349 2019
33
A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4-NTRK3 fusion. 61
30175468 2018
34
Subcutaneous Phaeohyphomycosis: A Clinical Mimic of Skin and Soft Tissue Neoplasms-A Descriptive Study from India. 61
30105639 2018
35
Solitary fibrous tumor of the stomach with high-grade sarcomatous dedifferentiation. 61
30473761 2018
36
Paradoxical Examination and Imaging Findings in a Case of Paratesticular Cutaneous Angioyxoma. 61
29894778 2018
37
Pancreatic primitive neuroectodermal tumor: Focus on radiological features and differential diagnosis - A case report and literature review. 61
30249906 2018
38
Applications of Ancillary Testing in the Cytologic Diagnosis of Soft Tissue Neoplasms. 61
30190145 2018
39
Surgical management of truncal soft tissue sarcoma and other selected soft tissue neoplasms. 61
30173529 2018
40
Application of ancillary studies in soft tissue cytology using a pattern-based approach. 61
30156774 2018
41
Rapidly growing subcutaneous mass in an infant. 61
30142742 2018
42
Histology of ancient soft tissue tumors: A review. 61
29776878 2018
43
Cytologic diagnosis of round cell sarcomas in the era of ancillary testing: an updated review. 61
31043308 2018
44
Malignant granular cell tumors: the role of electron microscopy in the definitive diagnosis of an extremely aggressive soft tissue neoplasm. 61
29737916 2018
45
Large intramuscular lipoma of the tongue. 61
29904473 2018
46
An incidental finding of an asymptomatic intraneural glomus tumor: A case report and review of the literature. 61
29272030 2018
47
Nail Unit Glomus Tumor with Myxoid and Symplastic Change Presenting with Longitudinal Erythronychia. 61
29998102 2018
48
Treatment of primary tracheal glomus tumors: Two case reports and a literature review. 61
29642190 2018
49
Desmoid Tumor as an Initial Presentation of Familial Adenomatous Polyposis: A Review of the Literature. 61
31482042 2018
50
Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition. 61
29439172 2018

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

Pathways related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 TSC2 TSC1 PTCH1 NF1 MDM2 KIT
2
Show member pathways
12.7 TSC2 TSC1 MDM2 GNAS CTNNB1 CDK4
3
Show member pathways
12.64 TSC2 TSC1 MDM2 KIT GNAS CTNNB1
4 12.52 PTCH1 MDM2 KIT GNAS CTNNB1 CDK4
5
Show member pathways
12.3 TSC2 TSC1 NF1 MDM2 HBEGF GNAS
6
Show member pathways
12.22 TSC2 TSC1 KIT GNAS
7 12.11 PTCH1 MDM2 HBEGF CTNNB1
8 11.96 TSC2 TSC1 MDM2 CDK4
9
Show member pathways
11.87 TSC2 MDM2 HBEGF CTNNB1
10 11.68 TSC2 TSC1 MDM2
11 11.62 TSC2 TSC1 NF1 MDM2 CTNNB1 CDK4
12 11.55 MDM2 HBEGF CDK4
13 11.38 TSC2 TSC1 CTNNB1
14 11.15 TSC2 TSC1 NF1 MDM2 CTNNB1 CDK4

GO Terms for Connective Tissue Benign Neoplasm

Cellular components related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle membrane GO:0030666 9.33 PTCH1 MDM2 HBEGF
2 perinuclear region of cytoplasm GO:0048471 9.17 TSC2 TSC1 PTCH1 GNAS CTNNB1 CDK4
3 TSC1-TSC2 complex GO:0033596 8.96 TSC2 TSC1

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 MDM2 KIT HBEGF CTNNB1 CDK4
2 positive regulation of gene expression GO:0010628 9.83 MDM2 KIT ERCC6 CTNNB1 CD34
3 heart development GO:0007507 9.81 TSC2 NF1 MDM2 CTNNB1
4 regulation of gene expression GO:0010468 9.78 NF1 MDM2 CTNNB1 CDK4
5 neural tube closure GO:0001843 9.67 TSC2 TSC1 PTCH1
6 response to drug GO:0042493 9.65 PTCH1 MDM2 GNAS CTNNB1 CDK4
7 hemopoiesis GO:0030097 9.63 KIT CTNNB1 CD34
8 negative regulation of cell proliferation GO:0008285 9.63 TSC2 TSC1 PTCH1 NF1 CTNNB1 CDC73
9 stem cell population maintenance GO:0019827 9.58 KIT CTNNB1 CDC73
10 negative regulation of oligodendrocyte differentiation GO:0048715 9.56 NF1 CTNNB1
11 regulation of insulin receptor signaling pathway GO:0046626 9.55 TSC2 CDK4
12 regulation of cell-matrix adhesion GO:0001952 9.54 TSC1 NF1
13 negative regulation of multicellular organism growth GO:0040015 9.52 PTCH1 GNAS
14 endodermal cell fate commitment GO:0001711 9.37 CTNNB1 CDC73
15 hair follicle placode formation GO:0060789 9.32 GNAS CTNNB1
16 tissue homeostasis GO:0001894 9.13 GNAS CTNNB1 CD34
17 regulation of cell proliferation GO:0042127 9.02 PTCH1 NF1 KIT CTNNB1 CDK4

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....